COVID-19 Impact on Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Market Insights and Forecast to 2026

COVID-19 Impact on Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Market Insights and Forecast to 2026

  • QYResearch
  • June 2020
  • Pharmaceutical
  • 116 pages

Report Description

1
1
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine

Segment by Application, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
Hospitals
Clinics
Others

Regional and Country-level Analysis
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Analysis
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs business, the date to enter into the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product introduction, recent developments, etc.
The major vendors covered:
Astellas Pharmaceuticals
Actavis
Pfizer
GlaxoSmithKline
Salix Pharmaceuticals Ltd
AstraZenenca
...

Have query on this report?

Make an Enquiry
1 Study Coverage
1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
1.2 Market Segments
1.3 Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
List of Tables
Table 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Segments
Table 2. Ranking of Global Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Preface
Table 5. Major Manufacturers of Eluxadoline

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074